‘Hadestown: The Musical’ Tops Specialty Box Office in Week 2 With $18.2M Cumulative Gross, Deadline Reports

Bleecker Street’s live-theater capture “Hadestown: The Musical” moved into the top spot for specialty box office performance in its second week, according to Deadline, with a weekly gross of $2 million. The report said the film played on 1,567 screens and reached a cumulative total of $18.2 million, making it one of the strongest performers among the category’s current slate.

The Deadline report framed the weekend’s results as part of a broader surge in the specialty segment, where theater and music-adjacent releases can benefit from limited-event screening behavior and targeted audiences. Deadline said the weekend was led by Spider-Man: Brand New Day, “The Odyssey,” and other studio-heavy releases, while specialty leaders such as “Hadestown: The Musical” continued to draw sustained attention from audiences seeking recorded versions of major stage productions.

In its comparison to other Broadway-to-screen titles, Deadline said “Hadestown: The Musical” surpassed “Hamilton” in the same specialty category milestone it discussed. The report did not provide additional breakdowns for each title’s exact timing or release pattern beyond the figures it cited for “Hadestown,” but it positioned the movie’s continued box office momentum as notable within the live-theater capture market.

Deadline also noted that independents, including “The Invite,” contributed to a busy weekend for theaters, suggesting that multiple non-studio releases were competing effectively alongside larger franchise material. The article’s emphasis on “one of the biggest weekends in box office history” pointed to unusually high overall activity, which can lift specialty results even when theater captures are not the largest per-theater earners.

The film capture’s rise in specialty performance matters for stakeholders across distribution and exhibition, including theater owners managing screen schedules, specialty programmers, and rights holders that license stage productions for cinema runs. For audiences, it indicates continued availability of major Broadway productions outside the theater, with the cinema format potentially offering a lower-cost alternative to traveling for performances, depending on local screenings.

It was not immediately clear from the Deadline reporting how long “Hadestown: The Musical” will continue in wide specialty circulation or whether additional weeks will be added beyond current screen counts. The report did not cite any specific extension, re-release plan, or supplemental engagements, focusing instead on the weekly box office snapshot and its relationship to the broader weekend lineup.

As specialty box office cycles turn, the next measure of impact will be whether “Hadestown” maintains its hold on top performance across subsequent weeks, and whether other live-theater captures can match its scale of screens and cumulative gross. For exhibitors, the practical question is how upcoming programming decisions balance blockbuster demand with specialty content that depends on both audience familiarity with the source production and the cinema’s willingness to schedule dedicated screenings.

For rights holders, labor, and production stakeholders, strong specialty runs can affect future negotiations around licensing terms, release windows, and marketing commitments tied to theatrical performance. The Deadline figures give a clear indication that at least one major Broadway-origin property is finding commercial traction in cinemas beyond its initial debut window, with its second-week results indicating continued audience pull.